I-Mab Biopharma, a Shangai, China-based company focusing on innovative Biologics in therapeutic areas of immuno-oncology and immuno-inflammation, completed a USD$220m Series C financing.
The round was led by Hony Capital, with participations from Hillhouse Capital, HOPU Investments, CDH Investment, Ally Bridge Group, Singapore-based EDBI, and existing investors C-Bridge Capital and Tasly Capital.
The company intends to use the proceeds to advance the pre-clinical and clinical development of a number of Best-in-Class and First-in-Class assets.
Led by Dr. Jingwu Zang, the founder and CEO, I-Mab is a biopharma innovative company specialized in oncology and autoimmune diseases. It has rapidly built a globally competitive pipeline through target biology, antibody engineering as well as pre-clinical & clinical development.
Currently, I-Mab has more than ten investigational drugs under development and partnerships with biotech and pharma companies, such as Genexine, Ferring Pharmaceuticals, MorphoSys AG, and CROs, which include WuXi Biologics, TigerMed and others.